Get the Stockscreener App
1.74
1.75%
0.03
After Hours:
1.66
-0.08
-4.60%
Compugen Ltd stock is traded at $1.74, with a volume of 232.13K.
It is up +1.75% in the last 24 hours and up +38.10% over the past month.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
See More
Previous Close:
$1.71
Open:
$1.71
24h Volume:
232.13K
Relative Volume:
0.88
Market Cap:
$137.46M
Revenue:
-
Net Income/Loss:
$1.60M
P/E Ratio:
58.00
EPS:
0.03
Net Cash Flow:
$-62.91M
1W Performance:
+18.37%
1M Performance:
+38.10%
6M Performance:
+5.45%
1Y Performance:
-19.07%
1-Day Range:
$1.65
$1.77
1-Week Range:
$1.45
$1.85
52-Week Range:
$1.13
$2.66
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
1.74 | 137.46M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Initiated | Oppenheimer | Outperform |
| Aug-05-22 | Downgrade | Jefferies | Buy → Hold |
| May-26-20 | Resumed | JMP Securities | Mkt Outperform |
| May-13-20 | Initiated | Stifel | Buy |
| May-07-20 | Initiated | SVB Leerink | Outperform |
| Apr-22-20 | Initiated | ROTH Capital | Buy |
| Mar-24-20 | Initiated | SunTrust | Buy |
| Jan-16-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-29-18 | Initiated | Oppenheimer | Outperform |
| Feb-01-16 | Resumed | Oppenheimer | Outperform |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Apr-23-15 | Resumed | Jefferies | Buy |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Feb-07-14 | Initiated | MLV & Co | Buy |
| Dec-28-09 | Reiterated | Cantor Fitzgerald | Buy |
| Jul-29-09 | Initiated | Cantor Fitzgerald | Buy |
View All
Compugen Ltd Stock (CGEN) Latest News
Compugen Ltd. (NASDAQ:CGEN) Shares Purchased by Squarepoint Ops LLC - Defense World
Coeptis Therapeutics (NASDAQ:COEP) and Compugen (NASDAQ:CGEN) Head to Head Comparison - Defense World
Northern Trust Corp Raises Stock Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
These Analysts Just Made An Incredible Downgrade To Their Compugen Ltd. (NASDAQ:CGEN) EPS Forecasts - Yahoo Finance
Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically - simplywall.st
Analysts Offer Predictions for Compugen FY2025 Earnings - Defense World
Q2 Earnings Forecast for Compugen Issued By Leerink Partnrs - Defense World
Compugen Ltd. (NASDAQ:CGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
Compugen: Q1 Earnings Snapshot - New Haven Register
Compugen Ltd (CGEN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - Yahoo Finance
Compugen’s Q1 2025: Clinical Progress and Financial Stability - TipRanks
Compugen earnings missed, revenue fell short of estimates By Investing.com - Investing.com South Africa
Compugen Q1 2025 Earnings Call Transcript - MarketBeat
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Transcript : Compugen Ltd., Q1 2025 Earnings Call, May 19, 2025 - marketscreener.com
Compugen Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Compugen earnings missed, revenue fell short of estimates - Investing.com Australia
Compugen Reports Q1 2025 Results and Strategic Developments - TipRanks
Compugen Reports First Quarter 2025 Results | CGEN Stock News - GuruFocus
Compugen Reports First Quarter 2025 Results - Yahoo Finance
Compugen (CGEN) to Release Earnings on Monday - Defense World
COMPUGEN Earnings Preview: Recent $CGEN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Compugen CEO Anat Cohen-Dayag to transition to executive chair - MSN
Raymond James Financial Inc. Acquires Shares of 67,041 Compugen Ltd. (NASDAQ:CGEN) - Defense World
Compugen (CGEN) Announces Leadership Transition for 2025 | CGEN Stock News - GuruFocus
Compugen Announces Leadership Transitions Effective September 2025 | CGEN Stock News - GuruFocus
Compugen Announces Leadership Transitions Effective September 2025 - marketscreener.com
Compugen Announces Leadership Transitions Effective September 20 - GuruFocus
Compugen Announces Leadership Changes Effective September 2025 - TipRanks
Compugen announces executive leadership changes By Investing.com - Investing.com India
Compugen announces executive leadership changes - Investing.com
Investor Network: Compugen Ltd. to Host Earnings Call - ACCESS Newswire
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025 | CGEN Stock News - GuruFocus
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025 - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
67,041 Shares in Compugen Ltd. (NASDAQ:CGEN) Acquired by Raymond James Financial Inc. - Defense World
Compugen (NASDAQ:CGEN) vs. Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) Financial Review - Defense World
Commonwealth Equity Services LLC Takes Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
Compugen Ltd. Announces Appointment of Alberto Sessa as Chief Financial Officer - marketscreener.com
Compugen at Stifel Forum: Strategic Insights on Immunotherapy Pipeline By Investing.com - Investing.com South Africa
Compugen at Stifel Forum: Strategic Insights on Immunotherapy Pipeline - Investing.com Australia
Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation? - simplywall.st
Compugen at Needham Conference: Strategic Immuno-Oncology Insights - Investing.com Australia
Compugen at Needham Conference: Strategic Immuno-Oncology Insights By Investing.com - Investing.com India
Compugen Ltd Stock (CGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):